Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

First systemic therapy for fatal childhood disease - recessive dystrophic epidermolysis bullosa

University of Minnesota Children's Hospital, Fairview physicians have performed the first bone marrow and cord blood transplant to treat recessive dystrophic epidermolysis bullosa (RDEB).

5 Nov 2007

Does neural cell adhesion molecule-180 predict survival in colorectal cancer?

When a person learns they are suffering from cancer, the first question in their mind is always: "How much time do I have?" Unfortunately, this is a question to which the researchers have long been seeking an absolute answer.

5 Nov 2007

New model of esophageal cancer

In the November 1st issue of G&D, a team of scientists led by Dr. Anil Rustgi (UPENN) presents an innovative new model of esophageal cancer, which holds great promise as an experimental platform to investigate the etiology and possible treatment of this devastating disease.

1 Nov 2007

How tumors respond to EGFR inhibitors

Three papers published this month in the open access general medical journal PLoS Medicine investigate how tumors respond to a an important class of drugs used in cancer chemotherapy, known as epidermal growth factor receptor (EGFR) inhibitors.

31 Oct 2007

Women still face cancer risk 25 years after treatment

Women are still at risk of developing invasive cancer of the cervix or vagina 25 years after being treated for pre-cancerous lesions, according to a study published today on bmj.com.

25 Oct 2007

Emerging cancer therapies and novel targets

What are the cancer drugs of tomorrow and how will they be developed? At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, researchers will present some answers to these and other pressing questions regarding emerging cancer therapeutics.

25 Oct 2007

New target for Hepatocellular carcinoma therapy

Hepatocellular carcinoma (HCC) is a major health problem worldwide. Currently, the only chance for obtaining a cure in patients with HCC is by either a surgical resection or liver transplantation.

25 Oct 2007

Cellular power plant fault explains abnormal metabolism of tumours

The increased consumption of glucose that tumour cells exhibit, was thought to be a cause of the extra demand of building blocks required to keep up with an uncontrolled cell growth, but now it is more accepted that it could be the effect of a programmed metabolic change that favours this malignant growth.

23 Oct 2007

Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma

Portal venous tumor thrombus (PVTT) is a crucial factor that can worsen the prognosis of patients with hepatocellular carcinoma (HCC).

18 Oct 2007

Is the spleen able to prohibit tumor cell proliferation?

Primary and metastatic tumors of the spleen are described as unusual, excluding involvement by lymphoma.

17 Oct 2007

Delisheng shows anti-cancer effects on hepatocellular carcinoma

Traditional Chinese medicine is world renowned. It has supernatural effects on some diseases, but the reason is still unknown. One such article was recently reported in the November 7 issue of the World Journal of Gastroenterology dealing with the great significance of a Chinese medicinal compound, "delisheng", for the therapy of HCC and its neoteric research method.

16 Oct 2007

Can liver cirrhosis be partially cured?

The diffusion of hepatitis C virus infection worldwide is astonishing. Liver cirrhosis is present in at least 10-20% of these infected patients, with highly increasing health care and emotional costs.

10 Oct 2007

Interleukin-8, key marker for colorectal cancer treatment

Colorectal cancer (CRC) is currently one of the three most frequent malignancies in Western industrial nations.

10 Oct 2007

Sir Martin Evans wins Nobel prize for stem cell research

Medical Research Council funded scientist Sir Martin Evans, has been awarded the Nobel Prize in Physiology or Medicine for 2007 alongside Mario R. Capecchi and Oliver Smithies for their discoveries of "principles for introducing specific gene modifications in mice by the use of embryonic stem cells".

9 Oct 2007

Proteins found that could be used to improve diagnosis of hepatocellular carcinoma

Researchers report in the October 2007 issue of Molecular & Cellular Proteomics that they have identified proteins that could be used to improve the diagnosis of hepatocellular carcinoma, the most common type of liver cancer.

8 Oct 2007

Researchers create modular, multi-functional drug delivery system

There are two aspects to creating an effective drug: finding a chemical compound that has the desired biological effect and minimal side-effects and then delivering it to the right place in the body for it to do its job.

8 Oct 2007

Cell's cytoskeleton may hold key to overcoming drug resistance in cancer

Researchers have uncovered a new way in which a cell protein protects cancer cells from a wide range of chemotherapeutic drugs, identifying a possible target for improving treatment outcomes for patients.

4 Oct 2007

Taxotere (docetaxel) granted FDA approval to treat locally advanced head and neck cancer prior to chemo and surgery

Sanofi-aventis announced that the U.S. Food and Drug Administration (FDA) has approved Taxotere (docetaxel) Injection Concentrate in combination with cisplatin and 5-fluorouracil for induction therapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN) before patients undergo chemoradiotherapy and surgery.

2 Oct 2007

New way to deliver agents for the treatment of skin cancer

Queen's University scientists have hit upon a revolutionary way to deliver agents for the treatment of skin cancer.

1 Oct 2007

Oncolytics Biotech reports positive interim results of UK phase Ia/Ib trials

Oncolytics Biotech Inc. has announced that an oral presentation covering interim results from a U.K. Phase Ia/Ib combination REOLYSIN and radiation clinical trial for patients with advanced or metastatic cancers is scheduled to be presented at the National Cancer Research Institute (NCRI) conference on October 2, 2007 in Birmingham, U.K.

29 Sep 2007